

CD45 (3H1363): sc-70699

BACKGROUND

CD45 has been identified as a transmembrane glycoprotein, broadly expressed among hematopoietic cells. Multiple isoforms of CD45 are distributed throughout the immune system according to cell type. These isoforms arise because of alternative splicing of exons 4, 5 and 6. The corresponding protein domains are characterized by the binding of monoclonal antibodies specific for CD45RA (exon 4), CD45RB (exon 5), CD45RC (exon 6) and CD45RO (exons 4 to 6 spliced out). The variation in these isoforms is localized to the extracellular domain of CD45, while the intracellular domain is conserved. CD45 functions as a phosphotyrosine phosphatase, a vital component for efficient tyrosine phosphorylation induction by the TCR/CD3 complex. The tyrosine phosphatase activity of CD45 is contained within the conserved intracellular domain. Src and Syk family protein tyrosine kinases are utilized by the TCR/CD3 complex to initiate signaling cascades. Several members of these two families, including Lck, Fyn and ZAP-70, have been implicated as physiological substrates of CD45.

REFERENCES

1. Trowbridge, I.S. 1978. Interspecies spleen-myeloma hybrid producing monoclonal antibodies against mouse lymphocyte surface glycoprotein, T200. *J. Exp. Med.* 148: 313-323.
2. West, K.P., et al. 1986. The demonstration of B cell, T cell and myeloid antigens in paraffin sections. *J. Pathol.* 150: 89-101.
3. Streuli, M., et al. 1987. Differential usage of three exons generates at least five different mRNAs encoding human leukocyte common antigens. *J. Exp. Med.* 166: 1548-1566.
4. Hall, P.A., et al. 1987. New marker of B lymphocytes, MB2: comparison with other lymphocyte subset markers active in conventionally processed tissue sections. *J. Clin. Pathol.* 40: 151-156.
5. Poppema, S., et al. 1987. Monoclonal antibodies (MT1, MT2, MB1, MB2, MB3) reactive with leukocyte subsets in paraffin-embedded tissue sections. *Am. J. Pathol.* 127: 418-429.

CHROMOSOMAL LOCATION

Genetic locus: PTPRC (human) mapping to 1q31.3.

SOURCE

CD45 (3H1363) is a rat monoclonal antibody raised against T lymphocytes of human origin.

PRODUCT

Each vial contains 200 µg IgG_{2b} in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin.

CD45 (3H1363) is available conjugated to either phycoerythrin (sc-70699 PE) or fluorescein (sc-70699 FITC), 200 µg/ml, for WB (RGB), IF, IHC(P) and FCM.

STORAGE

Store at 4° C, **DO NOT FREEZE**. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

APPLICATIONS


CD45 (3H1363) is recommended for detection of CD45 of human origin by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000), immunoprecipitation [1-2 µg per 100-500 µg of total protein (1 ml of cell lysate)] and flow cytometry (1 µg per 1 x 10⁶ cells).

Suitable for use as control antibody for CD45 siRNA (h): sc-29251, CD45 shRNA Plasmid (h): sc-29251-SH and CD45 shRNA (h) Lentiviral Particles: sc-29251-V.

Molecular Weight of CD45: 180-220 kDa.

Positive Controls: BJAB whole cell lysate: sc-2207, Ramos cell lysate: sc-2216 or GA-10 whole cell lysate: sc-364230.

DATA



CD45 (3H1363): sc-70699. Western blot analysis of CD45 expression in GA-10 (A), BJAB (B), CCRF-CEM (C), SUP-T1 (D), THP-1 (E) and Raji (F) whole cell lysates.


CD45 (3H1363): sc-70699. Western blot analysis of CD45 expression in GA-10 (A), human PBL (B) and Ramos (C) whole cell lysates.

SELECT PRODUCT CITATIONS

1. Lin, E., et al. 2017. High-throughput microfluidic labyrinth for the label-free isolation of circulating tumor cells. *Cell Syst.* 5: 295-304.
2. Zhao, Y., et al. 2019. Isolation of circulating tumor cells in patients undergoing surgery for esophageal cancer and a specific confirmation method. *Oncol. Lett.* 17: 3817-3825.
3. Hong, S.L., et al. 2019. High-performance multiplex microvalves fabrication and using for tumor cells staining on a microfluidic chip. *Biomed. Microdevices* 21: 87.
4. Rivera-Báez, L., et al. 2020. Expansion of circulating tumor cells from patients with locally advanced pancreatic cancer enable patient derived xenografts and functional studies for personalized medicine. *Cancers* 12: 1011.
5. Zhang, Q., et al. 2020. Circulating tumor cells in whole process management of gastrointestinal stromal tumor in a real-life setting. *Saudi J. Gastroenterol.* 26: 160-167.

RESEARCH USE

For research use only, not for use in diagnostic procedures.



See **CD45 (35-Z6): sc-1178** for CD45 antibody conjugates, including AC, HRP, FITC, PE, and Alexa Fluor[®] 488, 546, 594, 647, 680 and 790.